BMS announces good news from oncology division, shares rise 7%

Bristol-Myers Squibb yesterday announced that FDA has approved Empliciti (elotuzumab) in combination with pomalidomide and dexamethasone (EPd) for the treatment of patients with multiple myeloma having received at least two prior therapies without any effect. Few hours before BMS had announced it had entered into an agreement with Infinity Pharmaceuticals, aimed at testing the PD-1 inhibitor Opdivo in combination with immunotherapy IPI-549, for bladder cancer. The first goal set by the companies is the Phase II MARIO-275 clinical trial on 150 patients. BMS’ shares have risen over 7% from the beginning of the week.

(Source: BMS)